Facts {#Sec1}
=====

Resistance to apoptosis has become the main obstacle for overcoming cancer progression.Ferroptosis is a type of cell death characterized by excess reactive oxygen species and intracellular iron, and is totally different from apoptosis.NcRNAs serve as important roles in biological processes of cancer.Regulation of ncRNAs to ferroptosis has been partially discovered.

Open Questions {#Sec2}
==============

Can ferroptosis become the direction around which to design cancer therapy in future?What are the roles of ncRNAs in regulation of ferroptosis?Can ncRNAs become markers to filter cancer patients who are fit for ferroptosis therapy or therapeutic targets of ferroptosis inducers?

Introduction {#Sec3}
============

Cancer progression including proliferation, metastasis and chemoresistance to drugs, has become serious obstacles in cancer therapy^[@CR1]^. Although multiple therapeutic manners including operation, targeted therapy, chemotherapy, and radiotherapy have shown satisfactory performance, progression occurs since cancer cells dysregulate apoptosis pathways via various manners^[@CR2],[@CR3]^. Therefore, new types of cancer therapy or drugs that eliminate cancer cells are urgently needed.

Ferroptosis is a type of programmed cell death discovered in 2012^[@CR4]^. Unlike apoptosis, ferroptosis is characterized by excess reactive oxygen species (ROS) and intracellular iron^[@CR5]^. Superabundant ROS induces peroxidation and disintegration of lipid membrane and cell death^[@CR6]^. Regulation of ferroptosis mainly depends on neutral reaction between reduced glutathione (GSH) and ROS^[@CR7]^. The exchange of glutamate and cystine is mediated by systemXc^−^, which is composed of solute carrier family 7 member 11 (SLC7A11) and solute carrier family 3 member 2 (SLC3A2), and offers the substrate cystine for GSH synthesis^[@CR8],[@CR9]^. Glutathione peroxidase 4 (GPX4) catelyzes interaction between GSH and ROS to reduce intracellular oxidative stress^[@CR10]^. Ferroptosis inducers can be divided into two classes based on regulation of neutral reaction to ROS. Class I ferroptosis inducers such as sorafenib, erastin and sulfasalazine, serve as blockers of systemXc^−^ and result in a drop of GSH levels^[@CR11],[@CR12]^. Class II ferroptosis inducers such as RSL3, FIN56, and ML162, inhibit function of GPX4^[@CR13],[@CR14]^. Numerous studies have confirmed that ferroptosis inducers such as RSL3 and sorafenib eliminates cancer cells^[@CR15],[@CR16]^. In addition, induction of ferroptosis via erastin and sulfasalazine improved effect of cytarabine and doxorubicin, and overcame cisplatin resistance of head and neck cancer^[@CR17],[@CR18]^. This suggests that ferroptosis may become a new mechanism around which to design cancer therapy. However, use of ferroptosis in cancer therapy still faces obstacles. First, the specific mechanisms underlying ferroptosis and the interaction between ferroptosis and other processes, such as apoptosis, necrosis, and autophagy are not totally known, so how to control ferroptosis in cancer is in dark. Second, ferroptosis occurs in normal cells. Ferroptosis has been shown to induce the elimination of nerve cells in Parkinson's disease^[@CR19]^. In addition, in acute kidney injury, ferroptosis participated in the death of renal tubular epithelial cells^[@CR20]^. Therefore, use of ferroptosis inducers may generate complications. New regulatory factors should be recognized to understand the true appearance of ferroptosis in cancer.

Noncoding RNAs (ncRNAs) are RNAs that account for nearly 98% of transcriptome^[@CR21]^. According to length and shapes, ncRNAs are divided into various types including microRNAs (miRNAs), PIWI-interacting RNAs (piRNAs), small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), long ncRNAs (lncRNAs), circular RNAs (circRNAs), transfer RNAs (tRNAs), and ribosomal RNAs (rRNAs)^[@CR22],[@CR23]^. NcRNAs participate in regulation of tumorigenesis via various biological processes such as chromatin modification, alternative splicing, competition with endogenous RNAs and interaction with proteins^[@CR24],[@CR25]^. For example, *miR-675-5p* promoted the metastasis of colorectal cancer cells via modulation of P53^[@CR26]^. Moreover, lncRNA *HOTAIR* served as an enhancer in epithelial-to-mesenchymal transition of breast cancer cells via competing with BRCA1^[@CR27]^. In addition, *circFOXO3* enhanced progression of prostate cancer through sponging *miR-29a-3p*^[@CR28]^. However, roles of ncRNAs in ferroptosis have not been fully determined.

In this review, we focus on summarizing the ncRNAs which have been found to associate with ferroptosis regulators GSH, iron, nuclear factor (erythroid-derived 2)-like 2 (NRF2) and ROS in cancer^[@CR5]^. Moreover, we predict the obstacles that may limit the exploration of ncRNAs in ferroptosis in cancer therapy and offer advice for future studies. We believe that a comprehensive understanding of the interactions between ncRNAs and ferroptosis may benefit clinical therapeutics to cancer

MiRNAs and ferroptosis {#Sec4}
----------------------

MiRNAs exhibit functions by binding to the 3′-untranslated regions of target mRNAs and suppressing their expression^[@CR29]^. Some studies have revealed a relationship between miRNAs and ferroptosis. In radioresistant cells, *miR-7-5p* inhibited ferroptosis via downregulating mitoferrin and thus reducing iron levels^[@CR30]^. Furthermore, *miR-9* and *miR-137* enhanced ferroptosis via reduction of intracellular GSH levels, *miR-9* inhibited synthesis of GSH and *miR-137* suppressed solute carrier family 1 member 5 (SLC1A5), a component of systemXc^−[@CR31]^. Moreover, *miR-6852* which was regulated by lncRNA *Linc00336*, inhibited growth of lung cancer cells via promoting ferroptosis^[@CR32]^. In the following sections, we will discuss the interactions between miRNAs and GSH, iron and NRF2 in cancer cells. The information of altered miRNAs in ferroptosis has been listed (Supplementary Table [1](#MOESM1){ref-type="media"}).

MiRNAs and GSH {#Sec5}
--------------

GSH is a scavengerof ROS and protects lipid membrane^[@CR33]^. Under physiological conditions, concentration of reduced GSH is about 10--100-fold more prevalent than the oxidized form. Under oxidative stress, reduced GSH is converted to oxidized form^[@CR34]^. Biosynthesis of GSH involves three steps: exchange of glutamic acid and cystine induced by systemXc^−^; synthesis of 𝛾-glutamylcysteine by glutamic acid and cysteine catalyzed via 𝛾-glutamylcysteine ligase (GCL); and synthesis of GSH via 𝛾-glutamylcysteine and glycine catalyzed by GSH synthetase^[@CR35]^. Function of GSH includes detoxification of exogenous or endogenous dangerous compounds catalyzed by GSH-S-transferases (GSTs) and GPXs^[@CR36]^. Current knowledge on relation between GSH and cancer are summarized in Table [1](#Tab1){ref-type="table"}, and the schematic diagram of these interactions is shown in Fig. [1a](#Fig1){ref-type="fig"}. *MiR-18a* and *miR-218* decreased GSH levels via targeting GCL in hepatocellular carcinoma and bladder cancer^[@CR37],[@CR38]^. Furthermore, in hepatocellular carcinoma and lung cancer, *miR-152* and *miR-155* decreased GSH levels via targeting GST^[@CR39],[@CR40]^. In addition, *miR-326* and *miR-27a* inhibited GSH levels in cancer cells via targeting other factors such as pyruvate kinase m 2 (PKM2), SLC7A11 and zinc finger and BTB domain containing 10 (ZBTB10)^[@CR41]--[@CR43]^. Additionally, downregulation of GSH by miRNAs such as *miR-21*, *miR-24-2*, *miR-497* and *miR‑503* has been observed in different cancer types, however, the specific mechanisms were not explored^[@CR44]--[@CR47]^. These findings indicate that miRNAs repress GSH levels via control of synthesis and consumption. The upregulation of GSH induced by miRNAs has been well-explored. GST was targeted by different miRNAs including *miR-124*, *let-7a-5p*, *miR-92b-3p*, *miR-129-5P*, *miR-144*, *miR-153-1/2*, *miR-302c-5p*, *miR-3664-5p*, *miR-3714*, *miR-513a-3p*, *miR-590-3p/5p*, *miR-130b*, *miR-186*, and *miR-133a/b*. These miRNAs bound to the 3′-untranslated regions of GST mRNA and inhibited GST expression, thus blocking GSH consumption and resulting in accumulation of intracellular GSH^[@CR48]--[@CR51]^. It is worth mentioning that *miR-133a/b* served as effective suppressors of GST in different cancer types, such as bladder cancer, lung cancer, prostate cancer, colorectal cancer, ovarian cancer and head and neck carcinoma. Inhibition of *miR-133a/b* reversed both increased GSH and insensitivity to drugs^[@CR51]--[@CR54]^. Furthermore, GPX family members are targeted by miRNAs and results in defect of ROS neutralization. In one report, GPX4 was decreased by *miR-181a-5p* in osteoarthritis^[@CR55]^. However, the relationship between GPX4 and miRNAs in cancer is still in dark. Only GPX2 and GPX3 have been found to be modulated by miRNAs such as *miR-17*, *miR-17-3p*, *miR-196a*, and *miR-921* in colorectal cancer, prostate cancer, and lung cancer^[@CR56]--[@CR59]^. Overall, regulation of GSH by miRNAs occurs mainly through control of GST and GPX family members. Since GSH has been shown to participate in growth of tumors and chemoresistance to drugs which induce intracellular oxidative stress, miRNAs may regulate ferroptosis and control cancer progression via modulation of GSH.Table 1Summary of GSH associated miRNAs in cancer.NameAssociated cancer typeTargetInfluence to GSHModel of evidenceReference*miR-27a*Bladder cancer, colorectal cancerSLC7A11, ZBTB10Up/DownCell culture, animal models^[@CR42],[@CR43]^*miR-143*Colorectal cancerGPXUpAnimal models^[@CR199]^*miR-17*Prostate cancerGPX2UpCell culture, animal models^[@CR56]^*miR-17-3p*Prostate cancerGPX2UpCell culture, animal models^[@CR57]^*miR-196a*Lung cancerGPX3UpCell culture, animal models^[@CR58]^*miR-921*Lung cancerGPX3UpCell culture^[@CR59]^*miR-124*Colorectal cancerGSTUpCell culture, animal models^[@CR48]^*Let-7a-5p*Prostate cancerGSTUpCell culture, animal models^[@CR49]^*miR-92b-3p*Prostate cancerGSTUpCell culture, animal models^[@CR49]^*miR-129-5P*Colorectal cancer cellsGSTUpCell culture^[@CR50]^*miR-144*Prostate cancerGSTUpCell culture, animal models^[@CR51]^*miR-153-1/2*Prostate cancerGSTUpCell culture, animal models^[@CR51]^*miR-302c-5p*Colorectal cancerGSTUpCell culture^[@CR50]^*miR-3664-5p*Colorectal cancerGSTUpCell culture^[@CR50]^*miR-3714*Colorectal cancerGSTUpCell culture^[@CR50]^*miR-513a-3p*Colorectal cancer, lung cancerGSTUpCell culture^[@CR200]^*miR-590-3p/5p*Prostate cancerGSTUpCell culture, animal models^[@CR51]^*miR-133a/b*Bladder cancer, lung cancer, prostate cancer, colorectal cancer, ovarian cancer, head and neck squamous cell carcinomaGSTUpCell culture, animal models^[@CR52],[@CR53],[@CR201]^*miR-130b*Ovarian cancerGSTUpCell culture^[@CR202]^*miR-186*Ovarian cancerGSTUpCell culture^[@CR203]^*miR-34b*Prostate cancerMYCUpCell culture^[@CR204]^*miR-K12-11*Kaposi's sarcomaxCTUpCell culture^[@CR205]^*miR-18a*Hepatocellular carcinomaGCLDownCell culture, animal models^[@CR37]^*miR-218*Bladder cancerGCLDownCell culture^[@CR38]^*miR-21*Lung cancerGSHDownCell culture^[@CR44]^*miR-24-2*Colorectal cancerGSHDownClinical samples^[@CR45]^*miR-497*Cervical cancerGSHDownCell culture^[@CR46]^*miR-503*Hepatocellular carcinomaGSHDownCell culture^[@CR47]^*miR-152*Hepatocellular carcinomaGSTDownCell culture^[@CR39]^*miR-155*Lung cancerGSTDownCell culture^[@CR40]^*miR-326*GliomaPKM2DownCell culture^[@CR41]^*miR-125b*Chronic lymphocytic leukemiasGSHUnknownCell culture^[@CR206]^Fig. 1Regulation of ncRNAs to ferroptosis.**a** Regulation of ncRNAs to GSH metabolism; **b** Regulation of ncRNAs to iron metabolism; **c** Regulation of ncRNAs to KEAP1-NRF2 pathway.

MiRNAs and iron {#Sec6}
---------------

Iron metabolism is another key factor in ferroptosis. Excessive iron increases ROS via Fenton reaction and ROS is neutralized by iron reversely^[@CR60]^. Metabolism of iron mainly includes interaction between transferrin (TF) and its receptor (TFR), import of iron via divalent metal transporter 1 (DMT1), storage of iron as ferritin and iron-sulfur cluster (ISC), and export of iron via ferroportin (FPN)^[@CR61],[@CR62]^. The specific realtion between miRNAs and iron is summarized in Table [2](#Tab2){ref-type="table"}, and the schematic diagram of these interactions are shown in Fig. [1b](#Fig1){ref-type="fig"}. In colorectal cancer, targeting of DMT1 by *miR-149* and *miR-19a* led to decreased iron import^[@CR63]^. Furthermore, in colorectal cancer and hepatocellular cancer, TFR was targeted by miRNAs including *miR-141*, *miR-145*, *miR-152*, *miR-182*, *miR-200a*, *miR-22*, *miR-31*, *miR-320*, *miR-758*, and *miR-194*^[@CR63]--[@CR65]^. This inhibition led to disruption of interaction between TF and TFR and the following decreased iron import. Thereinto, *miR-194* suppressed the expression of both TFR and FPN in colorectal cancer^[@CR63]^. FPN was also targeted by *miR-150*, *miR-17-5p*, *miR-20a*, and *miR-492* in hepatocellular carcinoma, multiple myeloma, lung cancer, and prostate cancer, respectively^[@CR66]--[@CR68]^. Furthermore, ferritin which is composed of ferritin heavy chain (FHC) and ferritin light chain (FLC), is controlled by miRNAs^[@CR69]^. FHC could be targeted by *miR-200b*, *miR-181a-5p*, *miR-19b-1-5p*, *miR-19b-3p*, *miR-210-3p*, *miR-362-5p*, *miR-616-3p*, and *miR-638* in prostate cancer, resulting in decreased intracellular iron^[@CR65],[@CR70],[@CR71]^. FLC could be targeted by *miR-133a* in colorectal cancer and breast cancer, and knockdown of *miR-133a* restored the reduced iron levels inside cancer cells^[@CR63],[@CR72]^. Among the miRNAs that regulate iron levels, *miR-210* serves as an important member. In colorectal cancer cells, *miR-210* was activated by hypoxia and then targeted ISCU to alter intracellular iron homeostasis^[@CR73]^. Furthermore, transfection of *miR-210* decreased the uptake of iron via TFR suppression^[@CR74]^. On the contrary, miRNAs can be modulated by iron. *MiR-107*, *miR-125b*, and *miR-30d* were inhibited by iron in hepatocellular carcinoma and ovarian cancer^[@CR75],[@CR76]^, and *miR-146a*, *miR-150*, *miR-214-3p* and *miR-584* were increased by iron in ovarian cancer and neuroblastoma^[@CR76],[@CR77]^. This phenomenon may derive from the induction of excess ROS by iron and the subsequent regulation of miRNAs transcription. Overall, different miRNAs regulate iron levels in various directions, and the imbalance of iron leads to run-away miRNA expression.Table 2Summary of iron associated miRNAs in cancer.NameAssociated cancer typeTargetInfluence to ironModel of evidenceReference*miR-150*Hepatocellular carcinomaFPNUpCell culture^[@CR76]^*miR-17-5p*Multiple myelomaFPNUpCell culture, animal models^[@CR66]^*miR-20a*Lung cancerFPNUpCell culture^[@CR67]^*miR-492*Prostate cancerFPNUpCell culture, animal models^[@CR68]^*miR-194*Colorectal cancerTFR1, FPN1UpClinical samples^[@CR63]^*miR-449a*GliomaCDGSH iron sulfur domain 2DownCell culture, animal models^[@CR207]^*miR-149*Colorectal cancerDMT1DownClinical samples^[@CR63]^*miR-19a*Colorectal cancerDMT1DownClinical samples^[@CR63]^*miR-181a-5p*Prostate cancerFHCDownCell culture, animal models^[@CR70]^*miR-19b-1-5p*Prostate cancerFHCDownCell culture, animal models^[@CR70]^*miR-19b-3p*Prostate cancerFHCDownCell culture, animal models^[@CR70]^*miR-210-3p*Prostate cancerFHCDownCell culture, animal models^[@CR70]^*miR-362-5p*Prostate cancerFHCDownCell culture, animal models^[@CR70]^*miR-616-3p*Prostate cancerFHCDownCell culture, animal models^[@CR70]^*miR-638*Prostate cancerFHCDownCell culture, animal models^[@CR70]^*miR-200b*Hepatocellular carcinoma, breast cancerFerritinDownCell culture^[@CR65],[@CR71]^*miR-133a*Colorectal cancer, breast cancerFLCDownCell culture^[@CR63],[@CR72]^*miR-29*Lung cancerIron-responsive element binding protein 2DownClinical samples^[@CR208]^*miR-210*Renal cancer, head and neck paragangliomas, breast cancer, colorectal cancer, and oropharyngeal squamous cell carcinomasISCU, TFR1DownCell culture, animal models^[@CR73],[@CR74],[@CR209]--[@CR211]^*miR-126*Malignant mesotheliomaMitochondria-destabilizing stress signalsDownCell culture, animal models^[@CR212]^*miR-7-5p*Ovarian cancer, colorectal cancerMitoferrinDownCell culture^[@CR30]^*miR-122*Hepatocellular cancerNocturninDownCell culture, animal models^[@CR213]^*miR-34a*Lung cancerP53DownCell culture, animal models^[@CR214]^*miR-141*Colorectal cancerTFR1DownClinical samples^[@CR63]^*miR-145*Colorectal cancerTFR1DownClinical samples^[@CR63]^*miR-152*Hepatocellular carcinomaTFR1DownCell culture, animal models^[@CR64]^*miR-182*Colorectal cancerTFR1DownClinical samples^[@CR63]^*miR-200a*Hepatocellular carcinomaTFR1DownCell culture^[@CR65]^*miR-22*Hepatocellular cancerTFR1DownCell culture^[@CR65]^*miR-31*Colorectal cancerTFR1DownClinical samples^[@CR63]^*miR-320*Hepatocellular cancerTFR1DownCell culture^[@CR65]^*miR-758*Colorectal cancerTFR1DownClinical samples^[@CR63]^*miR-107*Hepatocellular carcinoma--Inhibited by ironCell culture, animal models^[@CR75]^*miR-125b*Ovarian cancer--Inhibited by ironCell culture^[@CR76]^*miR-30d*Hepatocellular carcinoma--Inhibited by ironCell culture, animal models^[@CR75]^*miR-146a*Ovarian cancer--Induced by ironCell culture^[@CR76]^*miR-150*Ovarian cancer--Induced by ironCell culture^[@CR76]^*miR-214-3p*Neuroblastoma--Induced by ironCell culture^[@CR77]^*miR-584*Neuroblastoma--Induced by ironCell culture^[@CR77]^

MiRNAs and NRF2 {#Sec7}
---------------

NRF2 serves as a transcriptional factor and activates downstream antioxidant factors. The expression of NRF2 mainly depends on Kelch-like ECh-Associated Protein 1 (KEAP1), which assembles Cullin3 to form the Cullin-E3 ligase complex and then degrades NRF2 protein via the ubiquitin-proteasome route^[@CR78]^. Inhibition of NRF2 has been confirmed to enhance ferroptosis^[@CR79]^. The specific information regarding interaction between miRNAs and NRF2 is listed in Table [3](#Tab3){ref-type="table"}, and the schematic diagram is shown in Fig. [1c](#Fig1){ref-type="fig"}. In esophageal cancer, *miR-129*, *miR-142*, *miR-144-3p*, *miR-450*, *miR-507*, and *miR-634* targeted the 3′-untranslated region of NRF2 mRNA and decreased NRF2 expression, resulting in an increase of ROS^[@CR80]--[@CR85]^. Among these miRNAs, *miR-144-3p* played an important role in the regulation of NRF2. Targeting NRF2 by *miR-144-3p* inhibited tumor progression in melanoma and acute myeloid leukemia^[@CR86]^, and increased the sensitivity of lung cancer cells to cisplatin^[@CR87]^, indicating the role of *miR‑144‑3p* in oxidative homeostasis. Other miRNAs that targeted NRF2 include *miR-144*, *miR-153*, *miR-200c*, and *miR-212-3p*, although their effects have not been explored^[@CR82],[@CR88]--[@CR90]^. Moreover, miRNAs regulate NRF2 via targeting KEAP1. In hepatocellular carcinoma, ovarian cancer, leukemia, and neuroblastoma cells, KEAP1 was targeted by *miR-141*, *miR-23a*, *miR-432*, *miR-7*, and *miR-200a*^[@CR88],[@CR91]--[@CR95]^. Thereinto, *miR-200a* served as an active role. In esophageal squamous cell carcinoma, methylseleninic acid activated KEAP1/NRF2 pathway via upregulating *miR-200a*, the latter inhibited KEAP1 expression and induced expression of NRF2^[@CR96]^. In breast cancer and pancreatic adenocarcinoma, *miR-200a* suppression reverted expression of KEAP1 and then inhibited NRF2 and promoted the anchorage-independent cell growth in vitro^[@CR97]^. In turn, NRF2 enhances miRNAs expression via binding to the antioxidative response element box. In myelocytic leukemia, *miR-125b* driven by NRF2 promoted leukemic cells survival. Inhibition of *miR-125b* enhanced responsiveness of leukemic cells towards chemotherapy^[@CR98]^. However, in oral squamous cell carcinoma, repression of *miR-125b* by peroxiredoxin like 2A (PRXL2A) protected cancer cells from drug-induced oxidative stress in an NRF2-depedent manner^[@CR99]^, indicating the mutual regulation between *miR-125b* and NRF2. In addition, expression of *miR-29B1*, *miR-129-3p*, and *miR-380-3p* was induced by NRF2 in acute myelocytic leukemia, hepatocellular carcinoma, and neuroblastoma^[@CR98],[@CR100],[@CR101]^. Conversely, *miR-181c*, *miR-378*, *miR-122*, *miR-17-5p*, *miR-1*, and *miR-206* were repressed by NRF2 in various cancer types^[@CR66],[@CR102]--[@CR107]^. Thereinto, inhibition of *miR-1* and *miR-206* was mediated by SOD1 induced by NRF2 but not the role of NRF2 as a transcriptional factor. In summary, miRNAs regulate NRF2 pathway through targeting KEAP1 and NRF2 mRNAs. Conversely, NRF2 controls miRNAs via transcription or downstream factor SOD1.Table 3Summary of NRF2 associated miRNAs in cancer.NameAssociated cancer typeTargetInfluence to NRF2Model of evidenceReference*miR-141*Hepatocellular carcinoma, ovarian cancerKEAP1UpCell culture^[@CR88],[@CR91]--[@CR93]^*miR-23a*LeukemicKEAP1UpCell culture, animal models^[@CR94]^*miR-432*Esophageal cancerKEAP1UpCell culture^[@CR92],[@CR95]^*miR-7*Neuroblastoma cellsKEAP1UpCell culture^[@CR92]^*miR-200a*Breast cancer, esophageal cancer, hepatocellular carcinoma, and pancreatic adenocarcinomasKEAP1,UpCell culture, animal models^[@CR81],[@CR92],[@CR96],[@CR97],[@CR215],[@CR216]^*miR-155*Lung cancerNRF2UpCell culture^[@CR217]^*miR-101*Hepatocellular carcinoma, prostate cancerNRF2, SOD1Up/DownCell culture, animal models^[@CR88],[@CR105],[@CR218]^*miR-1*Lung cancer, prostate cancerNRF2, SOD1Up/Inhibited by NRF2Cell culture, animal models^[@CR105],[@CR107]^*miR-206*Lung cancer, prostate cancerNRF2, SOD1Up/Inhibited by NRF2Cell culture, animal models^[@CR105]--[@CR107]^*miR-148b*Endometrial cancerERMP1DownCell culture^[@CR219]^*miR-129*Esophageal cancerNRF2DownCell culture, animal models^[@CR80]^*miR-129-5a*Esophageal cancerNRF2DownCell culture, animal models^[@CR80],[@CR81]^*miR-129-5p*Esophageal cancerNRF2DownCell culture, animal models^[@CR80]^*miR-142*Esophageal cancerNRF2DownCell culture^[@CR82]^*miR-144*Hepatocellular carcinoma, leukemia, hepatocellular carcinoma, neuroblastomaNRF2DownCell culture^[@CR88],[@CR89]^*miR-144-3p*Melanoma, lung cancer, and acute myeloid leukemiaNRF2DownCell culture^[@CR86],[@CR87],[@CR220],[@CR221]^*miR-153*Neuroblastoma, breast cancer, and oral squamous cell carcinomaNRF2DownCell culture^[@CR82],[@CR90]^*miR-200c*Lung cancerNRF2DownCell culture, animal models^[@CR222]^*miR-212-3p*MelanomaNRF2DownCell culture^[@CR86]^*miR-23b-3p*MelanomaNRF2DownCell culture^[@CR86]^*miR-27*NeuroblastomaNRF2DownCell culture, animal models^[@CR223]^*miR-28*Breast cancer, esophageal cancerNRF2DownCell culture^[@CR81],[@CR224]^*miR-340*Hepatocellular carcinoma, esophageal cancerNRF2DownCell culture^[@CR85],[@CR88],[@CR92]^*miR-34a*Breast cancer, colon cancer, ovarian cancer, and lung cancerNRF2DownCell culture^[@CR225],[@CR226]^*miR-450*Esophageal cancerNRF2DownCell culture^[@CR83]^*miR-450a*Esophageal cancerNRF2DownCell culture, animal models^[@CR80],[@CR81]^*miR-495*Nonsmall-cell lung cancerNRF2DownCell culture^[@CR227]^*miR-507*Esophageal cancerNRF2DownCell culture, animal models^[@CR80],[@CR81],[@CR84]^*miR-634*Esophageal cancerNRF2DownCell culture, animal models^[@CR80],[@CR81],[@CR85]^*miR-93*Pancreatic adenocarcinomas, breast cancerNRF2DownCell culture, animal models^[@CR97],[@CR221]^*miR-93-5p*MelanomaNRF2DownClinical samples^[@CR86]^*miR-125b*Acute myelocytic leukemia, oral squamous cell carcinoma, and renal cancerNRF2Down/Induced by NRF2Cell culture, animal models^[@CR98],[@CR99],[@CR228]^*miR-181c*Colorectal cancer--Inhibited by NRF2Cell culture, animal models^[@CR102]^*miR-378*Mucoepidermoid carcinoma--Inhibited by NRF2Cell culture, animal models^[@CR103]^*miR-122*Hepatocellular carcinoma--Inhibited by NRF2Cell culture^[@CR104]^*miR-17-5p*Multiple myeloma--Inhibited by NRF2Cell culture, animal models^[@CR66]^*miR-29B1*Acute myelocytic leukemia--Induced by NRF2Cell culture^[@CR98]^*miR-129-3p*Hepatocellular carcinoma--Induced by NRF2Cell culture, animal models^[@CR100]^*miR-380-3p*Neuroblastoma--Induced by NRF2Cell culture, animal models^[@CR101]^

MiRNAs and ROS {#Sec8}
--------------

In addition to factors above, miRNAs regulate ROS via other mechanisms. The information of miRNAs that are related to ROS in cancer is listed in Table [4](#Tab4){ref-type="table"}. MiRNAs can positively regulate ROS levels. For example, *miR-21* whose expression increased with tumor grade, has been identified to enhance ROS level in lung cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, ovarian cancer, and prostate cancer^[@CR108]--[@CR113]^. Mechanically, *miR-21* targeted STAT3, proline oxidase (POX), and programmed cell death 4 (PDCD4) to induce oxidative stress^[@CR114]--[@CR116]^. Moreover, *miR-146a* has attracted much attention. In ovarian cancer, *miR-146a* repressed SOD2 expression and inhibited proliferation of cancer cells and enhanced chemosensitivity to drugs^[@CR117]^. In lung cancer, suppression of *miR-146a* restored catalase and inhibited ROS induction, and protected cancer cells from cisplatin-induced cytotoxicity^[@CR118]^. In addition, overexpression of *miR-124*, *miR-526b*, and *miR-655* led to excess ROS via thioredoxin reductase 1 in breast cancer^[@CR119],[@CR120]^. Furthermore, the antioxidant enzyme SOD1 was downregulated by stable expression of *miR-143* or *miR-145* in colorectal cancer^[@CR121]^. This indicates that miRNAs enhance intracellular ROS via different manners. On the other hand, in lung cancer, *miR-99* suppressed the invasion and migration of cancer cells via targeting NOX4-mediated ROS production^[@CR122]^. Additionally, *miR-520* and *miR-373* reduced ROS via targeting NF-κB and TGF-β signaling pathways and repressed growth and lymph node metastasis of breast cancer^[@CR123]^. Other miRNAs such as *let-7*, *miR-137*, *miR-193b*, *miR‑199*, and *miR-26a*, have been found to decrease ROS level in cancer cells via diverse targets such as heme oxygenase-1, C-MYC, and triglyceride^[@CR124]--[@CR128]^, indicating that miRNAs inhibit ROS level. Conversely, *miR-133a*, *miR-150-3p*, *miR-1915-3p*, *miR-206*, *miR-34*, *miR-638*, and *miR-182* were activated by oxidative stress and then played a role in the subsequent biological processes^[@CR129]--[@CR133]^. Moreover, *miR-125*, *miR-145-5p*, *miR-17-5p*, *miR-199*, and *miR-17-92*, were decreased by excess intracellular ROS^[@CR134]--[@CR137]^. Among them, *miR-125b* plays a dual role in oxidative homeostasis. As discussed above, *miR-125b* serves as a regulator of NRF2. In addition, *miR-125b* could be inhibited by ROS via a DNMT1-dependent DNA methylation in ovarian cancer^[@CR140]^. Moreover, although *miR-21* has been discussed as the enhancer of ROS in breast cancer, DNA damage induced by ROS led to activation of *miR-21* via NF-κB, indicating the interaction between miRNAs and ROS^[@CR138]^. In total, we can infer that altered levels of GSH, iron, and NRF2 are not the only methods by which miRNAs regulate ROS and vice versa in, miRNAs and ROS can also regulate each other in various pathways.Table 4Summary of ROS associated miRNAs in cancer.NameAssociated cancer typeTargetInfluence to ROSModel of evidenceReference*miR-124*Non-small cell lung cancerTXNRD1UpCell culture^[@CR120]^*miR-125a*OsteosarcomaEstrogen-related receptor alphaUpCell culture^[@CR229]^*miR-128a*MedulloblastomaBMI-1UpCell culture^[@CR230]^*miR-139-5p*Breast cancerUnknownUpCell culture, animal models^[@CR231]^*miR-143*Colorectal cancerSOD1UpCell culture^[@CR121]^*miR-146a*Lung cancer, ovarian CancerCatalase, SOD2UpCell culture, animal models^[@CR117],[@CR118]^*miR-146b-5p*LeukemicUnknownUpCell culture^[@CR232]^*miR-15*Colorectal cancer, cancer stem cellsC-MYCUpCell culture, animal models^[@CR233]^*miR-155*Glioma, pancreatic cancerMAPK13, MAPK14, and Foxo3aUpCell culture, animal models^[@CR234],[@CR235]^*miR-15a-3p*Lung cancerP53UpCell culture^[@CR236]^*miR-16*Colorectal cancer, cancer stem cellsC-MYCUpCell culture, animal models^[@CR233]^*miR-186*Colorectal cancerCKIIUpCell culture^[@CR237]^*miR-193a-3p*GliomaγH2AXUpCell culture^[@CR238]^*miR-210*Cancer stem cells, gliomaP53UpCell culture, animal models^[@CR239]^*miR-212*Colorectal cancerMnSODUpClinical samples^[@CR240]^*miR-216b*Colorectal cancerCKIIUpCell culture^[@CR237]^*miR-22*Hepatocellular carcinomaSIRT-1UpCell culture^[@CR241]^*miR-223*Breast cancerHAX-1UpCell culture^[@CR242]^*miR-23b-3p*Acute myeloid leukemiaPrxIIIUpCell culture^[@CR243]^*miR-25-5p*Colorectal cancerSOX10UpCell culture^[@CR244]^*miR-26a-5p*Acute myeloid leukemiaPrxIIIUpCell culture^[@CR243]^*miR-26b*Small cell lung cancerMyeloid cell leukemia 1 proteinUpCell culture, animal models^[@CR245]^*miR-30*Gastric cancerP53UpCell culture^[@CR246]^*miR-337-3p*Colorectal cancerCKIIUpCell culture^[@CR237]^*miR-34c*Nonsmall cell lung cancerHMGB1UpCell culture^[@CR247]^*miR-371-3p*Lung cancerPRDX6UpCell culture, animal models^[@CR248]^*miR-422a*Gastric cancerPDK2UpCell culture, animal models^[@CR249]^*miR-4485*Breast cancerMitochondrial proteinUpCell culture, animal models^[@CR133]^*miR-4673*Lung cancer8-Oxoguanine-DNA Glycosylase-1UpCell culture^[@CR250]^*miR-504*Lung cancerP53UpCell culture^[@CR251]^*miR-506*Lung cancerP53, NF-κBUpCell culture, animal models^[@CR252]^*miR-509*Breast cancerP53UpCell culture^[@CR253]^*miR-526b*Breast cancerThioredoxin Reductase 1UpCell culture^[@CR119]^*miR-551b*Lung cancerMUC1UpCell culture^[@CR254]^*miR-655*Breast cancerThioredoxin Reductase 1UpCell culture^[@CR119]^*miR-661*Colorectal cancerHexose-6-phosphate dehydrogenase, pyruvate kinase M2UpCell culture^[@CR255]^*miR-760*Colorectal cancerCKIIUpCell culture^[@CR237]^*miR-92*Hepatocellular carcinomaUnknownUpClinical samples^[@CR256]^*miR-128*Glioma, hepatocellular carcinomaPKM2Up/DownCell culture^[@CR257]^*miR-145*Colorectal cancer, hepatocellular carcinomaSOD1, PKM2Up/DownCell culture^[@CR121],[@CR258]^*miR-211*Myeloma, oral carcinomaPRKAA1, TCF12Up/DownCell culture, animal models^[@CR259],[@CR260]^*miR-222*Hepatocellular carcinoma, breast cancerNF-κB, TGF-βUp/DownCell culture, animal models^[@CR261],[@CR262]^*miR-23a/b*Myeloma, renal cancerC-MYC, POXUp/DownCell culture, animal models^[@CR263],[@CR264]^*miR-29*Ovarian cancer, lung cancer, and lymphomaC-MYC, SIRT1Up/DownCell culture, animal models^[@CR265],[@CR266]^*miR-34a*Gastric cancer, gliomaNOX2Up/DownCell culture^[@CR267]^*Let-7*Hepatocellular carcinoma, prostate cancer, and pancreatic cancerHeme oxygenase-1, P53Up/DownCell culture, animal models^[@CR123],[@CR268]^*miR-33a*Glioma, hepatocellular carcinomaSIRT6Up/DownCell culture, animal models^[@CR269]^*miR-221*Hepatocellular carcinoma, breast cancerNF-κB, TGF-β, and DICERUp/Down/Induced by ROSCell culture, animal models^[@CR261],[@CR262],[@CR270]^*miR-21*Lung cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, ovarian cancer, and prostate cancerSOD, MAPK, SOD2, Glucose, NFκB, STAT3, POX, and PDCD4Up/Down/Induced by ROSCell culture, animal models^[@CR108],[@CR112],[@CR114],[@CR271]^*miR-17-92*Gastric cancer, lung cancerC-MYC, P53, and NFκBUp/Down/Inhibited by ROSCell culture^[@CR137],[@CR272],[@CR273]^*miR-181*Hepatocellular carcinoma, uterine leiomyomaUnknownUp/Induced by ROSCell culture^[@CR132],[@CR274]^*miR-200*Breast cancer, cancer stem cells, hepatocellular carcinoma, and lung cancerP53, PRDX2, GAPB/NRF2, SESN1Up/Induced by ROSCell culture, animal models^[@CR222],[@CR275]--[@CR277]^*miR-34*Cancer stem cells, bladder cancer, lung cancerC-MYC, P53Up/Induced by ROSCell culture^[@CR278],[@CR279]^*miR-182*Uterine leiomyoma, lung cancerPDK4Up/Induced by ROSCell culture, animal models^[@CR132],[@CR133]^*miR-199*Gastric cancer, ovarian cancerDNMT1Up/Inhibited by ROSCell culture^[@CR134]^*miR-20a*Breast cancer, pancreatic cancerBECN1, ATG16L1, and SQSTM1Up/Inhibited by ROSCell culture, animal models^[@CR136],[@CR280]^*miR-125b*Hepatocellular carcinoma, ovarian cancer, and breast cancerHexokinase 2, DNMT1, and HAX-1Up/Inhibited by ROSCell culture, animal models^[@CR228],[@CR281]^*miR-1246*Breast cancerNF-κB, TGF-βDownCell culture^[@CR124]^*miR-137*Ovarian cancerC-MYCDownCell culture, animal models^[@CR125]^*miR-193b*LiposarcomaAntioxidant methionine sulfoxide reductase ADownCell culture, animal models^[@CR127]^*miR-199a-3p*Testicular cancerTranscription factor specificity protein 1DownCell culture^[@CR126]^*miR-26a*Hepatocellular carcinomaTriglyceride, totalcholesterol, malondialdehydeDownCell culture^[@CR128]^*miR-30c-2-3p*Breast cancerNF-κB, TGF-βDownCell culture^[@CR282]^*miR-346*Ovarian cancerGSK3BDownCell culture^[@CR283]^*miR-373*Breast cancerNF-κB, TGF-βDownCell culture, animal models^[@CR123]^*miR-520*Breast cancerNF-κB, TGF-βDownCell culture, animal models^[@CR123]^*miR-7*Nonsmall cell lung cancerMAFGDownCell culture^[@CR284]^*miR-885-5p*Hepatocellular carcinomaTIGARDownCell culture^[@CR285]^*miR-99a*Lung cancerNOX4DownCell culture, animal models^[@CR122]^*miR-133a*Rhabdomyosarcoma9Induced by ROSCell culture, animal models^[@CR129]^*miR-150-3p*Hepatocellular carcinoma--Induced by ROSCell culture^[@CR130]^*miR-1915-3p*Hepatocellular Carcinoma--Induced by ROSCell culture^[@CR130]^*miR-206*Rhabdomyosarcoma--Induced by ROSCell culture, animal models^[@CR131]^*miR-34a-3p*Hepatocellular carcinoma--Induced by ROSCell culture, animal models^[@CR129]^*miR-34a-5p*Hepatocellular carcinoma--Induced by ROSCell culture^[@CR130]^*miR-638*Hepatocellular carcinoma--Induced by ROSCell culture^[@CR130]^*miR-125*Gastric cancer--Inhibited by ROSCell culture^[@CR134]^*miR-145-5p*Gastric cancer--Inhibited by ROSCell culture, animal models^[@CR135]^*miR-17-5p*Pancreatic cancer--Inhibited by ROSCell culture, animal models^[@CR136]^*miR-27a*Pancreatic cancer, colorectal cancer--Inhibited by ROSCell culture, animal models^[@CR286]^*miR-328*Gastric cancer--Inhibited by ROSCell culture, animal models^[@CR287]^*miR-329*Breast cancer--Inhibited by ROSCell culture, animal models^[@CR288]^*miR-362-3p*Breast cancer--Inhibited by ROSCell culture, animal models^[@CR288]^

LncRNAs and ferroptosis {#Sec9}
-----------------------

LncRNAs mainly serve as regulators of transcription factors in nucleus or as sponges of miRNAs in cytoplasm^[@CR139]^. *Linc00336* was promoted by lymphoid-specific helicase in lung cancer and inhibited ferroptosis via sponging *miR-6852*^[@CR32]^. Furthermore, in breast cancer and lung cancer, lncRNA *P53rra* bound to Ras GTPase-activating protein-(SH3domain)-Binding Protein 1 (G3BP1) and displaced P53 from a G3BP1 complex, resulting in retention of P53 in nucleus and downregulation of SLC7A11^[@CR140]^. In addition, ferroptosis inducer erastin upregulated lncRNA GA binding protein transcription factor subunit beta 1 (GABPB1) antisense RNA 1 (*Gabpb1-AS1*), which suppressed GABPB1 and led to downregulation of peroxiredoxin-5 peroxidase and suppression of cellular antioxidant capacity in hepatocellular carcinoma^[@CR141]^. Interaction between lncRNAs and ferroptosis has been listed (Supplementary Table [1](#MOESM1){ref-type="media"}), and the relationship between lncRNAs and ferroptosis associated factors is summarized in Table [5](#Tab5){ref-type="table"}. The schematic diagram of these interactions is shown in Fig. [1](#Fig1){ref-type="fig"}.Table 5Summary of GSH, iron, NRF2, and ROS associated lncRNAs in cancer.Control pointNameAssociated cancer typeTargetInfluence to control pointModel of evidenceReferenceGSH*Linc01419*Esophageal squamous cell carcinomaGSTUpClinical samples^[@CR144]^*Neat1*Hepatocellular carcinomaGSTUpCell culture^[@CR143]^*H19*Ovarian cancerGCLC, GCLM, GSTUp/DownCell culture, animal models^[@CR145]^*Xist*Colorectal cancerGSTDownCell culture, animal models^[@CR48]^*Ror*Breast cancerGSTDownCell culture, animal models^[@CR142]^Iron*Pvt1*Hepatocellular carcinoma*miR-150*/HIG2UpCell culture, animal models^[@CR146]^*H19*Myeloid leukemia*miR-675*Inhibited by ironCell culture^[@CR147]^NRF2*Aatbc*Bladder cancerNRF2DownCell culture, animal models^[@CR148]^*Kral*Hepatocellular carcinomaKEAP1DownCell culture^[@CR91]^*Malat1*Multiple myelomaKEAP1DownCell culture, animal models^[@CR149]^*H19*Ovarian cancerNRF2DownCell culture, animal models^[@CR145]^*Scal1*Lung cancer--Induced by NRF2Cell culture^[@CR92]^*Loc344887*Gallbladder cancer--Induced by NRF2Cell culture^[@CR150]^ROS*Meg3*Lung cancerP53UpCell culture^[@CR154]^*Uca1*Bladder cancer*miR-16*DownCell culture^[@CR151]^*Gas5*MelanomaG6PDDownCell culture^[@CR153]^*H19*Hepatocellular carcinomaMAPK/ERK signaling pathwayDownCell culture^[@CR152]^*Miat*Neuroblastoma, glioblastomaMAPK7, FUT8, and MCL1UnknownCell culture^[@CR289]--[@CR295]^

LncRNAs and ferroptosis associated factors {#Sec10}
------------------------------------------

Since there are only a few studies about lncRNAs and ferroptosis factors, we will discuss them together. Regulation of GSH by lncRNAs in cancer mainly depends on GST and GCL^[@CR46]^. In breast cancer, knockdown of lncRNA *Ror* led to reduced multidrug resistance-associated P-glycoprotein and GST expression, resulting in restored sensitivity of breast cancer cells to tamoxifen^[@CR142]^. Similarly, in colorectal cancer, knockdown of lncRNA *Xist* inhibited doxorubicin resistance via suppressing GST and increasing GSH^[@CR48]^. Furthermore, in hepatocellular carcinoma cells, silencing lncRNA *Neat1* inhibited IL-6-induced STAT3 phosphorylation which contributed to the increase of GST^[@CR143]^. In addition, lncRNA *Linc01419* bound to the promoter region of *GSTP1* and recruited DNA methyltransferase, increasing promoter methylation and decreasing GST expression in esophageal squamous cell carcinoma^[@CR144]^. Moreover, knockdown of lncRNA *H19* resulted in recovery of cisplatin sensitivity via reduction of GCL and GST^[@CR145]^. In total, regulation of GSH by lncRNAs mainly depends on GST and GCL. Moreover, in hepatocellular carcinoma, silencing of lncRNA *Pvt1* inhibited TFR expression and obstructed iron uptake via *miR-150*^[@CR146]^. Furthermore, silencing of FHC in leukemia cells induced production of ROS and altered downstream genes via increasing *H19* and *miR-657* expression^[@CR147]^. This means that lncRNAs are associated with iron metabolism in cancer cells. Moreover, in bladder cancer, suppression of NRF2 by lncRNA associated transcript in bladder cancer (*Aatbc*) resulted in apoptosis^[@CR148]^. In multiple myeloma, metastasis associated lung adenocarcinoma transcript 1 (*Malat1*) which has been proved to play a role in various cancers, inhibited NRF2 via activation of their negative regulator KEAP1^[@CR149]^. Furthermore, overexpression of Keap1 regulation-associated lncRNA (*Kral*) inhibited NRF2 via increasing KEAP1 expression, and reversed the resistance of hepatocellular carcinoma cells to 5-fluorouracil^[@CR91]^. Therefore, lncRNAs regulate NRF2 expression via direct and indirect manners. On the contrary, NRF2 participates in regulation of lncRNAs. In gallbladder cancer, downregulation of lncRNA *loc344887* suppressed cell proliferation and decreased migration and invasion. Further studies found that *loc344887* was upregulated after ectopic expression of NRF2^[@CR150]^. In a recent study, NRF2 activated smoke and cancer-associated lncRNA 1 (*Scal1*) and induced oxidative stress protection. Knockdown of NRF2 suppressed *Scal1* and alleviated the proliferation of lung cancer cells^[@CR92]^. In sum, lncRNAs can regulate NRF2 by directly controlling expression or modulating KEAP1 indirectly, and NRF2 can regulate lncRNAs expression reversely.

Other than the factors above, lncRNAs regulate ROS levels via various mechanisms. In bladder cancer, lncRNA urothelial cancer associated 1 (*Uca1*) decreased ROS level via targeting *miR-16* which led to decreased GSH synthetase^[@CR151]^. Furthermore, in hepatocellular carcinoma, downregulation of *H19* increased ROS via MAPK/ERK signaling pathway and reversed chemotherapy resistance^[@CR152]^. Moreover, knockdown of lncRNA growth arrest specific 5 (*Gas5*) in melanoma enhanced intracellular ROS via increased superoxide anion and NADPH oxidase 4 (NOX4)-oxidized GSH^[@CR153]^. In lung cancer cells, the intracellular oxidative stress induced by paclitaxel was attenuated by knockdown of maternally expressed 3 (*Meg3*), and *Meg3* overexpression induced cell death and increased sensitivity to paclitaxel in an ROS-dependent manner^[@CR154]^. In total, lncRNAs influence ROS metabolism via control of GSH, iron, NRF2 and other factors, and these factors can regulate lncRNAs expression reversely.

Other ncRNAs and ferroptosis {#Sec11}
----------------------------

CircRNAs, tRNAs, rRNAs, piRNAs, snRNAs, and snoRNAs are also contained in family of noncoding RNAs^[@CR21]^. However, studies on the relations between these ncRNAs and ferroptosis are few. The interactions have been listed (Supplementary Table [2](#MOESM2){ref-type="media"}). The schematic diagram of these interactions is shown in Fig. [1](#Fig1){ref-type="fig"}.

CircRNAs {#Sec12}
--------

CircRNAs are covalently closed, single-stranded RNA molecules derive from exons via alternative mRNA splicing^[@CR22]^. Several studies have uncovered function of circRNAs in ferroptosis. In glioma, *circ-TTBK2* enhanced cell proliferation and invasion and inhibited ferroptosis via sponging *miR-761* and subsequent ITGB8 activation, knockdown of *circ-TTBK2* promoted erastin-induced ferroptosis^[@CR155]^. Furthermore, *circ0008035* inhibited ferroptosis in gastric cancer via *miR-599*/EIF4A1 axis. Knockdown of *circ0008035* enhanced anticancer effect of erastin and RSL3 via increased iron accumulation and lipid peroxidation^[@CR156]^. According to ferroptosis associated factors, in gastric cancer, *circPVT1* promoted multidrug resistance by enhancing P-gp and GSTP. MRNA levels of P-gp and GSTP were obviously repressed after downregulation of *circ-PVT1* in paclitaxel-resistant gastric cancer cells^[@CR157]^. Moreover, high-throughout microarray-based circRNA profiling revealed that 526 circRNAs were dysregulated in cervical cancer cells, and bioinformatic analyses indicated that these circRNAs participated mainly in GSH metabolism^[@CR158]^. However, associated miRNAs and downstream factors were not screened. Thus, further studies on the modulation of ferroptosis by circRNAs are needed.

TRNAs {#Sec13}
-----

TRNAs serve as adapter molecules between mRNAs and proteins. The interaction between tRNAs and ferroptosis includes two possible manners. First, tRNAs are required in the synthesis of ferroptosis associated factors such as SLC7A11, GPX4, and IREB2, thus the mutation of tRNAs may alter the expression of these factors and then influence ferroptosis^[@CR217]^. Second, tRNAs have multiple interaction partners including aminoacyl-tRNA-synthetases, mRNAs, ribosomes and translation factors^[@CR159]^. Among them, cysteinyl-tRNA synthetase plays a role in ferroptosis. In fibrosarcoma, rhabdomyosarcoma and pancreatic carcinoma, loss of cysteinyl-tRNA synthetase suppressed erastin-induced ferroptosis via increasing intracellular GSH and transsulfuration, and inhibition of the transsulfuration pathway resensitized cells to erastin^[@CR160]^. Interestingly, tRNAs mutation may control ferroptosis in an opposite manner. Selenocysteine which is formed from serine at the respective tRNA, is a component of GPXs. However, in hepatoma, colorectal cancer and breast cancer, the mutation of tRNA led to decline of selenoprotein expression except GPX4 and GPX1, and weak ferroptosis alteration^[@CR161]--[@CR163]^. This indicates that tRNAs modulate GSH levels mainly via synthesis but not metabolism. In addition, tRNAs influence ROS levels via various manners. Lung cancer mouse model with deletion of selenocysteine-tRNA gene exhibited ROS accumulation and increased susceptibility to lymph nodules metastasis^[@CR164]^. Additionally, Queuine-modified tRNAs promoted cellular antioxidant defense via catalase, SOD, GPX, and GSH reductase and inhibited lymphoma^[@CR165]^. In total, tRNAs decrease GSH synthesis and increase ferroptosis without modulating GPX4, while on the other hand, tRNAs enhance the antioxidant defense system and then inhibit ferroptosis.

RRNAs {#Sec14}
-----

RRNAs constitute the structural and functional core of ribosomes^[@CR166]^. Some reports have provided clues for role of rRNAs in ferroptosis. In cervical cancer, NRF2 was found to contain a highly conserved 18S rRNA binding site on 5′ untranslated region that is required for internal initiation. Deletion of this site remarkably enhanced translation, indicating that the 18S rRNA regulates NRF2 expression^[@CR167]^. In another study, hepatoma cells treated with ethidium bromide exhibited a 70% decrease in the 16S/18S rRNA ratio and enhanced NRF2 expression^[@CR168]^. However, whether NRF2 and 18S rRNA are mutually regulated remains unclear. Regarding ROS, nuclear mitotic apparatus protein (NuMA) is involved in cellular events such as DNA damage response, apoptosis, and P53-mediated growth arrest. In breast cancer cells, NuMA bound to 18S and 28S rRNAs and localized to rDNA promoter regions. Downregulation of NuMA expression triggered nucleolar oxidative stress and decreased pre-rRNA synthesis^[@CR169]^. Furthermore, in leukemia HL-60 cells treated with iron chelator deferoxamine, rRNA synthesis in nucleoli was inhibited^[@CR170]^. In conclusion, interaction between rRNAs and ferroptosis has not been completely uncovered. Role of ribosomes as the place in which proteins related to ferroptosis are synthesized may provide clues for further studies.

PiRNAs, snRNAs, and snoRNAs {#Sec15}
---------------------------

PiRNAs are the class of small ncRNA molecules distinct from miRNAs in that they are larger, lack sequence conservation, and are more complex^[@CR171]^. PiRNAs are involved in tumorigenesis of variety cancers^[@CR172]^. However, studies on piRNAs and ferroptosis are few. In prostate cancer, piR-31470 formed a complex with piwi-like RNA-mediated gene silencing 4 (PIWIL4). This complex recruited DNMT1, DNA methyltransferase 3 alpha, and methyl-CpG binding domain protein 2 to initiate and maintain the hypermethylation and inactivation of GSTP1. Overexpression of piR-31470 inhibited GSTP1 expression and increased vulnerability to oxidative stress and DNA damage in human prostate epithelial RWPE1 cells, resulting in tumorigenesis^[@CR173]^. However, the GSTP1 inactivation may inhibit tumor growth via induction of ferroptosis once the tumors are formed. Clearly, further studies are needed to explore the roles of piRNAs in different stages of cancer. SnoRNAs are a class of small RNA molecules that mediate modifications of rRNAs, tRNAs, and snRNAs. The snoRNA ACA11 was overexpressed in multiple myeloma cells, increasing ROS and resulting in protein production and cell proliferation^[@CR174]^. There are currently no reports on ferroptosis and snRNAs which mediate post-transcriptional splicing in gene expression. In cervical cancer and osteosarcoma, assembly chaperones and core proteins devoted to snRNA maturation contributed to recruiting trimethylguanosine synthase 1 to selenoprotein mRNAs including GPX1 for cap hypermethylation^[@CR175]^. Future studies should focus on the possible regulation of snRNAs towards GPX families. In sum, further studies are needed to explore functions of circRNAs, tRNA, rRNAs, piRNAs, snoRNAs and snRNAs in ferroptosis. Furthermore, the network of factors modulating ferroptosis remains to be established. As ferroptosis is a process of dynamic equilibrium, any alteration of the associated factors may intersect with others. For example, GSH maintains the cytosolic labile iron pool via formation of iron-GSH complexes^[@CR176]^. In addition, GSH regulates iron trafficking, and inhibition of GSH synthesis leads to diminished iron efflux following nitric oxide exposure^[@CR177]^. Moreover, iron is exported via multidrug resistant protein 1 (MRP1), a known transporter of GSH conjugates^[@CR178]^. GSH depletion, MRP1 inhibition or MRP1 knock-out leads to decreased iron release upon nitric oxide treatment^[@CR179]^. Conversely, the secondary increase in ROS induced by iron stimulates GSH production, indicating that iron and GSH are interconnected^[@CR46]^. Moreover, targets of NRF2 play a critical role in mediating iron/heme metabolism. Both FTL and FTH, the key iron storage protein, as well as FPN, which is responsible for cellular iron efflux, are controlled by NRF2^[@CR180],[@CR181]^. In addition, a number of integral GSH synthesis and metabolism related enzymes including both the catalytic and modulatory subunits of GCLC, GCLM, GSS, and SLC7A11, are under the control of NRF2^[@CR182]--[@CR184]^. In total, regulation of ferroptosis are linked together, modulation of GSH, iron and NRF2 by ncRNAs may result in further change of each other, and finally alter ferroptosis process.

Clinical application potential of ncRNA-associated ferroptosis {#Sec16}
--------------------------------------------------------------

Targeting ncRNAs in cancer has yielded some promising results, however, application of ferroptosis via an ncRNA-dependent manner in clinic is facing obstacles. Inadequate understanding of specific mechanisms results in the limited use of ncRNA modifiers in ferroptosis. Furthermore, cell death occurs in a variety of ways, and numerous ncRNAs may be simultaneously regulated, thus how to ensure that the alteration of associated ncRNAs leads to ferroptosis is another problem. Moreover, ncRNAs act in various ways that may intersect with ferroptosis. For example, ferroptosis inducer *miR-210* and *H19* could modulate autophagy via targeting BECN1, ATG7, SIRT1, and HIF-1α^[@CR185]--[@CR188]^. In addition, *miR-146a* could regulat ROS modulator catalase and SOD2 which repressed mitochondrial function^[@CR189],[@CR190]^. Alteration of autophagy or mitochondrial function resulted in multiple pathologic changes such as neuroinflammation, neurodegeneration, vessel remodeling and myocardial fibrosis, thus how to overcome these possible complications should be considered^[@CR191]--[@CR194]^. In addition, some pathways such as the KEAP1-NRF2 axis, is inhibited by multiple miRNAs and lncRNAs and promotes ferroptosis. Nevertheless, the repression of KEAP1-NRF2 results in the defect in cleaning of ROS and leads to susceptibility to DNA damage and tumorigenesis^[@CR195],[@CR196]^. To solve these problems, future studies should address the following points. First, more ncRNAs should be identified. A ferroptosis-associated ncRNA screening platform should be established to identify the spectrum of ferroptosis associated ncRNAs and those specific to certain cancers. Second, more intensive studies using complex molecular biological experiments, such as chromosome immunoprecipitation, RNA immunoprecipitation, RNA pull-down, luciferase assays, and RNA truncation should be performed to explore the precise roles of ncRNAs in ferroptosis. Third, in order to translate fundamental experimental results into clinic, functions of ncRNAs in ferroptosis should be tested in animal models. Transgenic mouse models should be established to verify the function of ncRNAs more clearly. Fourth, in order to ensure whether ferroptosis is modulated by ncRNAs, accurate detection of ROS and iron levels, and observation of mitochondrial morphology in tumor tissues are needed. Furthermore, primary culture of tumor cells from patients should be performed to explore whether the proliferation of cancer cells is enhanced by Fer-1, which is the specific inhibitor of ferroptosis. The involvement of ncRNAs in ferroptosis in cancer can be verified in knockdown or overexpression studies. Finally, since ferroptosis occurs in not only tumors but also normal tissues, and as above, ferroptosis regulation by ncRNAs may activate other biological processes and even increase the susceptibility to tumorigenesis. Thus, both ferroptosis-related ncRNAs and associated markers of cell death, senescence, and remodeling should be assessed in patients who are suitable for ferroptosis-associated therapy. In addition, adverse events, dose-limiting toxicities and therapeutic effects should be carefully monitored through rigorous detection of organ functions, imaging of vital organs and tumors, and hematological changes during the application of ferroptosis inducers in clinic. After all, as cancer is a developmental process, the collaboration between multidisciplinary teams should be made to obtain rational therapy regimens to enhance therapeutic effect and alleviate complications.

Conclusions and perspectives {#Sec17}
----------------------------

Cancer cells may be intrinsically insensitive or evolve and develop resistance to apoptosis, resulting in cancer progression^[@CR197]^. Under the development of molecular biological technologies, identification of new targets or methods to eliminate cancer cells has attracted substantial attention. Ferroptosis is a recently recognized form of programmed cell death that relies on excess intracellular ROS and consequent lipid peroxidation^[@CR198]^. Ferroptosis has been successfully applied to limit tumor growth and overcome the resistance of cancer cells to apoptosis, indicating that it may be useful as a new therapeutic approach^[@CR3]^. Nevertheless, the application of ferroptosis inducers in cancer therapy is limited, mainly because the specific mechanisms underlying ferroptosis remain unexplored.

NcRNAs have been proved to regulate gene expression by various manners. Numerous ncRNAs have been found to regulate behaviors of cancer cells. In recent years, researchers have examined some ferroptosis-associated ncRNAs in cancer cells. Nevertheless, the specific regulatory mechanisms have not been explored. Therefore, wider and deeper studies to explore the function of ncRNAs in ferroptosis are needed. In this review, the landscape of ncRNAs associated with ferroptosis in cancer thus far is summarized. In addition, possible obstacles during application of ncRNA-associated ferroptosis in clinic are put forward and associated solutions are suggested. However, the information summarized in this review is not sufficient to support the application of ferroptosis inducers in cancer, more ncRNAs should be identified and deeper researches should be performed. In conclusion, ncRNAs may become markers to filter cancer patients who are fit for ferroptosis therapy and become therapeutic targets of ferroptosis inducers.
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